A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

Key Inclusion Criteria for all trial participants:

- Age ≥ 18 years at screening

- Male subjects with partners of child-bearing potential must be willing to use condoms
from the time of the first intake of study drug until completion of follow-up

- Mean Arterial Pressure (MAP) ≥ 85 mmHg at screening visit

Key inclusion for Patient Groups 1 and 2

- If on treatment with non-selective beta blockers (NSBB), stable dose since ≥ 8 weeks
prior to screening, with no planned dose change of the therapy during study conduct.
All other medications stable 4 weeks prior to screening.

- Patient Group 1: Patients with CTP A (with liver stiffness >15 kPa during screening)
and without a previous decompensation event [ascites, variceal hemorrhage,
encephalopathy, or jaundice (except Gilbert's disease or hemolysis when bilirubin will
be almost exclusively indirect hyperbilirubinemia)]

- Patient Group 2: Patients with CTP B (with liver stiffness >15 kPa during screening)

Key inclusion for Healthy Volunteer group

-Subjects who are healthy, according to the investigator's assessment, individually matched
to a participant among Patient Groups 1 and 2 according to the following criteria: age
within ± 5 years, body weight within ± 15%, and gender

Key exclusion for all trial participants

- Ongoing chronic alcohol or drug use, which in the investigator's opinion, makes the
patient an unreliable trial participant or unlikely to complete the trial.

- History of relevant orthostatic hypotension, fainting spells, or blackouts based on
the investigator´s judgment

Key exclusion for Patient Groups

- Patient Group 2: treatment-refractory ascites

- Patient Group 2: recent decompensation event (refractory ascites, recurrent variceal
hemorrhage, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis or
hepatorenal syndrome) within 6 weeks of screening